Background: KRAS mutant (KRAS MT) and RAS/BRAF wild type (RAS WT) colorectal cancer (CRC) responds differently to targeted agents. A better understanding of early effects on signal transduction following exposure to targeted agents may explain this and inform future therapeutic strategies. Methods: A panel of 25 CRC cell lines (10 KRAS MT, 15 RAS WT) and 13 samples isolated from CRC patients' (pt) serous effusions were used. Using a multiplex antibodybased platform, simultaneous changes in 60 phosphorylated (p) proteins were quantified following 1-hour exposure to clinically used concentrations of: gefitinib, PI3K inhibitor: pictilisib, AZD5363, everolimus, trametinib and vemurafenib. Statistical analysis included logistic regression, T tests and Spearman's correlation. Results: Collectively pMEK was the most commonly upregulated protein in KRAS MT cell lines; 55% KRAS MT vs 18% RAS WT, a difference that was significant (P < 0.05) with pictilisib and gefitinib. Triplicate validation with pictilisib confirmed upregulation of pMEK, as well as pERK, pMSK, pGSK3a in KRAS MT but not RAS WT cell lines. KRAS MT cells had a higher mean pictilisib half maximal inhibitory concentration (P < 0.05), being highest in cells with the greatest pMEK rise. Validation with gefitinib confirmed consistent downregulation of pMEK, pMSK, pGSK3a/b, pPRAS40 and pS6 in sensitive RAS WT but not KRAS MT cells (P < 0.05), despite comparable decrease of pEGFR. Gefitinib sensitivity was related to the degree of downregulation of the aforementioned proteins. In 10 KRAS MT pt samples, pMEK upregulation was most commonly seen with pictilisib (38% of pts). As in cell lines, gefitinib led to upregulation of intracellular effectors in KRAS MT pt samples e.g. mTOR in 40% of pts. In RAS WT cells compensatory activation of receptor tyrosine kinases was the commonest rewiring feature, e.g. pFGFR1 upregulation with gefitinib in 40% of cell lines and 66% of pts. Conclusions: There are significant differences in the rewiring of signal transduction between KRAS MT and RAS WT CRC cells exposed to clinically relevant concentrations of PI3K and EGFR inhibitors. These differences can help devise/refine future strategies to combine targeted agents in CRC.
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Results:
We found consistent hyperactivation of the PI3K-AKT pathway coupled to the activation of multiple RTKs such as HER2, HER3 and IGF1R in resistant cells when compared to parental cells. Resistant clones exhibit an epithelial phenotype, more pronounced for mesenchymal-like parental cell lines of the CMS4 cluster (HCT116 and SW480). Either selective knockdown of these RTKs or treatment with the pan-HER inhibitor afatinib (BIBW2992) failed to revert the resistance phenotype in our cellular model, while treatment with pictilisib (GDC-0941, selective PI3Ka inhibitor) was able to restore the sensitivity to the drug combination. No new genetic alteration was detected. Conclusions: Our in vitro preliminary data demonstrate that PI3K activation plays a central role in the acquired resistance to the combination of anti-EGFR and MEK-i in KRAS mutated colorectal cancer cell lines. PI3K activation is achieved through concurrent activation of multiple RTKs such as HER2, HER3 and IGF1R, suggesting a cooperative mechanism. Legal entity responsible for the study: Department of Precision Medicine -Universit a della Campania Luigi Vanvitelli. Background: Tumour signalling and progression is strongly dependent on the tumour microenvironment, comprising components like extracellular matrix, surrounding stromal cells and signalling molecules including secreted proteins. However, little is known whether extracellular amino acids correlate with specific growth behaviour of defined melanoma cell lines. It was the aim of this study to identify components of a possible cross talk between slow and fast-growing melanoma cells. Methods: We have investigated the amino acid composition as well as acetate and pyruvate of the secretome of human melanoma cells representing early slow growth phase (WM35, WM278, WM793b and VM21) and rapid growth phase of metastatic cells (A375, 518a2, 6F and WM8). Subsequently, amino acid profiles were evaluated by multivariate data analysis, i.e. principle component analysis and partial least squares regression. Significant changes in the amino acid composition of media were analysed for biological significance with proliferation, migration and invasion assays. Results: Proliferation assays and a principle component analysis revealed a stringent difference between the fast and slow growing melanoma cells. Upon inhibition of the mevalonate pathway, glutamic acid and alanine were identified as the central difference in the conditional media. Supplementing media with glutamic acid and the combination with alanine significantly accelerated the proliferation, migration and invasion of early stage melanoma cells, but not metastatic cells. Interestingly, co-culture of early stage and metastatic melanoma cells further corroborate these findings, indicating cross talk between tumour cells. Conclusions: Our results confirm for the first time that amino acid profiles from conditional media differ between stage dependent growth and treatment. Hence, changes in amino acid composition of media from melanoma cells derived from different disease states reflect a stage dependent adaptation with functional consequences on proliferation, migration, aggressiveness and survival. Thus, identification of glutamic acid mediated signalling may open pharmacological targeting in early melanoma stages. Legal entity responsible for the study: Martin Hohenegger. 
